Characterizing the Frequency of Pharmacogenomic Biomarker-Guided Prescribing for Drugs with Pharmacogenomic Biomarker information in the FDA Labelling: A Pilot Study Using Data from an Electronic Health Record
You must log in to view this content. All contents are accessible to AMIA members and meeting attendees. If you are interested in purchasing proceedings, please contact us at mail@amia.org